Tolazamide
CAS No. : 1156-19-0
(Synonyms: U-17835)
| Size | Price | Stock |
|---|---|---|
| 5mg | $60 | In-stock |
| 10mg | $80 | In-stock |
| 25mg | $120 | In-stock |
| 50mg | $155 | In-stock |
| 100mg | $200 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-B0920 |
| M.Wt: | 311.40 |
| Formula: | C14H21N3O3S |
| Purity: | >98 % |
| Solubility: | DMSO : ≥ 39 mg/mL |
Tolazamide (U-17835) is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC50 = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA[1][2][3].
In Vitro:Tolazamide (0.1 nM-1 mM) inhibits Diazoxide (HY-B1140)-evoked responses dose-dependently in SUR1-Kir6.2 transfected HEK293 cells[2].
In Vivo:Tolazamide (40-400 μg/mL, 2 h) attenuates gluconeogenesis with both doses in control rats and inhibits gluconeogenesis in the liver tissue of diabetic rats with high concentration[4].
Tolazamide (40-400 μg/mL, 1.5 h) attenuates ketogenesis (nanomoles of palmitate converted per min/mg DNA) from 5.2 to 3.5 and 2.7 with 40 and 400 μg/mL, respectively in the liver tissue of diabetic rats [4].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Tolazamide
- Cat. No.:
- HY-B0920
- Quantity:
Your information is safe with us.